Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementation of an electronic patient-reported measure of barriers to antiretroviral therapy adherence with the Opal patient portal: Protocol for a mixed method type 3 hybrid pilot study at a large Montreal HIV clinic.
Engler K, Vicente S, Ma Y, Hijal T, Cox J, Ahmed S, Klein M, Achiche S, Pant Pai N, de Pokomandy A, Lacombe K, Lebouché B. Engler K, et al. Among authors: lacombe k. PLoS One. 2021 Dec 30;16(12):e0261006. doi: 10.1371/journal.pone.0261006. eCollection 2021. PLoS One. 2021. PMID: 34969046 Free PMC article.
Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME. Sacks-Davis R, et al. Among authors: lacombe k. J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25051. doi: 10.1002/jia2.25051. J Int AIDS Soc. 2018. PMID: 29633559 Free PMC article.
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Mercade GE, Kho D, Petoumenos K, Marks P, Tatsch F, Dos Santos AGP, Gane E; SMART-C Study Group. Dore GJ, et al. Among authors: lacombe k. J Hepatol. 2020 Mar;72(3):431-440. doi: 10.1016/j.jhep.2019.10.010. Epub 2019 Oct 23. J Hepatol. 2020. PMID: 31655134 Free article. Clinical Trial.
Acceptability of a Patient Portal (Opal) in HIV Clinical Care: A Feasibility Study.
Chu D, Schuster T, Lessard D, Mate K, Engler K, Ma Y, Abulkhir A, Arora A, Long S, de Pokomandy A, Lacombe K, Rougier H, Cox J, Kronfli N, Hijal T, Kildea J, Routy JP, Asselah J, Lebouché B. Chu D, et al. Among authors: lacombe k. J Pers Med. 2021 Feb 16;11(2):134. doi: 10.3390/jpm11020134. J Pers Med. 2021. PMID: 33669439 Free PMC article.
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC).
van Santen DK, Stewart A, Doyle JS, Stoové MA, Asselin J, Klein MB, Young J, Berenguer J, Jarrin I, Lacombe K, Wittkop L, Leleux O, Salmon D, Bonnet F, Rauch A, Mugglin C, Matthews G, Prins M, Smit C, Boyd A, van der Valk M, Sacks-Davis R, Hellard ME; InCHEHC Study Group. van Santen DK, et al. Among authors: lacombe k. Int J Epidemiol. 2024 Feb 1;53(1):dyad154. doi: 10.1093/ije/dyad154. Int J Epidemiol. 2024. PMID: 38066671 Free PMC article. No abstract available.
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R, van Santen DK, Boyd A, Young J, Stewart A, Doyle JS, Rauch A, Mugglin C, Klein M, van der Valk M, Smit C, Jarrin I, Berenguer J, Lacombe K, Requena MB, Wittkop L, Leleux O, Bonnet F, Salmon D, Matthews GV, Guy R, Martin NK, Spelman T, Prins M, Stoove M, Hellard M; InCHEHC Collaboration. Sacks-Davis R, et al. Among authors: lacombe k. Lancet HIV. 2024 Feb;11(2):e106-e116. doi: 10.1016/S2352-3018(23)00267-9. Epub 2024 Jan 12. Lancet HIV. 2024. PMID: 38224708
Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).
Marcellin F, Di Beo V, Aumaitre H, Mora M, Wittkop L, Duvivier C, Protopopescu C, Lacombe K, Esterle L, Berenger C, Gilbert C, Bouchaud O, Poizot-Martin I, Sogni P, Salmon-Ceron D, Carrieri P; ANRS CO13 HEPAVIH Study Group. Marcellin F, et al. Among authors: lacombe k. J Hepatol. 2020 Mar;72(3):588-591. doi: 10.1016/j.jhep.2019.10.019. Epub 2020 Jan 7. J Hepatol. 2020. PMID: 31924411 No abstract available.
Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ, Boyd A, Sacks-Davis R, van Santen DK, Smit C, Martinello M, Stoove M, Berenguer J, Wittkop L, Klein MB, Rauch A, Salmon D, Lacombe K, Stewart A, Schinkel J, Doyle JS, Hellard M, van der Valk M, Matthews GV; InCHEHC study group. Isfordink CJ, et al. Among authors: lacombe k. Lancet Public Health. 2023 Apr;8(4):e294-e304. doi: 10.1016/S2468-2667(23)00056-7. Lancet Public Health. 2023. PMID: 36965984 Free article.
375 results